BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Azacitidine: trial readouts and FDA decisions

4 upcoming industry Phase 2/3 readout(s) in the next 90 days, 0 upcoming FDA event(s), 1 readout(s) in the last 180 days and 0 FDA event(s) in the last 12 months. Sponsors: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd., Sellas Life Sciences Group, OncoVerity, Inc., AbbVie, Aptose Biosciences Inc.. Drug names come from ClinicalTrials.gov intervention names and FDA records, lightly normalised; one drug can appear under several names (code, generic, brand).

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-12-01 est.P2Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.NCT06858618 FCN-338 in Combination With Azacitidine or Chemotherapy in Myeloid NeoplasmsSafety; Antitumor Activity; PK Profileactive not recruiting47
2026-12-30 est.P1/P2Sellas Life Sciences Group SLSNCT04588922 Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AMLHematologic Malignanciesrecruiting160
2027-01 est.P2OncoVerity, Inc.NCT06384261 A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive TherapyLeukemia, Myeloid, Acuteactive not recruiting140
2027-02 est.P1/P2AbbVie ABBVNCT04086264 IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid LeukemiaAcute Myeloid Leukemiaactive not recruiting218

Readouts, last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11 est.P1/P2Aptose Biosciences Inc.NCT03850574 Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory AcuteLeukemia, Myeloid, Acute; Refractory AML; Relapsed Adult AML; Myelodysplastic Syndrome With Excess Brecruiting240

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.